J Gynecol Oncol.  2008 Dec;19(4):256-260. 10.3802/jgo.2008.19.4.256.

The effect of adjuvant hormonal therapy on the endometrium and ovary of breast cancer patients

• Kim HS
• Jeon YT
• Kim YB

• KMID: 2173416
• DOI: http://doi.org/10.3802/jgo.2008.19.4.256

Abstract

OBJECTIVE
To investigate the effect of adjuvant hormonal therapy on the endometrium and ovary of breast cancer patients.
METHODS
A retrospective review was performed on the 207 patients who had taken tamoxifen or anastrozole, as adjuvant hormonal therapy after breast cancer surgery between January 2003 and December 2006. Gynecologic surveillance constituted of ultrasonographic exam of the endometrial thickness and ovarian cyst formation. The patients were classified into three groups and analyzed; premenopausal/postmenopausal women receiving tamoxifen and women receiving anastrozole.
RESULTS
Mean duration of follow up was 20.6+/-6.6 months. There was no difference of mean endometrial thickness before hormonal therapy among the three groups (p=0.327). In women receiving tamoxifen, the endometrium was continuously thickened in proportion to the duration of the therapy irrespective of menopausal status while it remained unchanged in women receiving anastrozole (p<0.05). Endometrial biopsies were performed in 28 patients receiving tamoxifen. The most common histologic finding was proliferative endometrium in premenopausal women (7/21) and atrophic endometrium in postmenopausal women (6/7). There was no case of endometrial cancer in both groups. Ovarian cyst was found in 32 women and the most were developed in premenopausal women receiving tamoxifen (30/32). All of them showed benign nature on transvaginal ultrasonographic findings.
CONCLUSION
Women undergoing adjuvant hormonal therapy after breast cancer surgery exhibited changes in the endometrium and ovary. However most changes were not a serious problem in this study and frequent gynecologic surveillance in these patients needs further investigation.

Keyword

Breast cancer; Tamoxifen; Anastrozole; Endometrium

MeSH Terms

Biopsy
Breast
Breast Neoplasms
Endometrial Neoplasms
Endometrium
Female
Follow-Up Studies
Humans
Nitriles
Ovarian Cysts
Ovary
Retrospective Studies
Tamoxifen
Triazoles
Nitriles
Tamoxifen
Triazoles

Figure

• 

  Fig. 1 Changes of endometrial thickness during adjuvant hormonal therapy after breast cancer surgery (p<0.05).

Reference

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005. 55:74–108.

2. Ries LAG, Melbert D, Krapcho M. SEER cancer statistics review, 1975-2004. 2007. Bethesda, MD: National Cancer Institute.

3. EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005. 365:1687–1717.

4. Hulka CA, Hall DA. Endometrial abnormalities associated with tamoxifen therapy for breast cancer: Sonographic and pathologic correlation. Am J Roentgenol. 1993. 160:809–812.

5. Mourits MJ, Van der Zee AG, Willemse PH, Ten Hoor KA, Hollema H, De vries EG. Discrepancy between ultrasonographic and hysteroscopic and pathologic endometrial findings in postmenopausal breast cancer patients using tamoxifen. Gynecol Oncol. 1999. 73:21–26.

6. Van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, Otter R, et al. Risk of endometrial cancer following breast cancer treatment with tamoxifen. Lancet. 1994. 343:448–452.

7. Shusan A, Peretz T, Uziely B, Lewin A, Mor-Yosef S. Ovarian cysts in premenopausal and postmenopausal tamoxifen treated women with breast cancer. Am J Obstet Gynecol. 1996. 174:141–144.

8. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 2000. 18:3758–3767.

9. Bonneterre J, Thurrimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol. 2000. 18:3748–3757.

10. Baum M. Current status of aromatase inhibitors in the management of breast cancer and critique of the NCIC MA-17 trial. Cancer Control. 2004. 11:217–221.

11. Gershanovich M, Chaudri HA, Campos D, Lurie H, Bonaventura A, Jeffrey M, et al. Letrozole, a new aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethamide in postmenopausal women with advanced breast cancer. Ann Oncol. 1998. 9:639–645.

12. Buzdar A, Douma J, Davidson N, Elledge R, Morgan M, Smith R, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol. 2001. 19:3357–3366.

13. Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with MA in postmenopausal women with advanced breast carcinoma. Cancer. 1997. 79:730–739.

14. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, et al. Exemestane is superior to megesterol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial. J Clin Oncol. 2000. 18:1399–1411.

15. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 2001. 19:2596–2606.

16. Brodie AM, Schwarzel WC, Shaikh AA, Bordie HJ. The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer. Endocrinology. 1977. 100:1684–1695.

17. Gal D, Kopel S, Bashevkin M, Lebowicz J, Lev R, Tancer ML. Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer. Gynecol Oncol. 1991. 42:120–123.

18. Lahti E, Blanco G, Kaupilla A, Apala-Sarkinen M, Taskinen PJ, Laatikain T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol. 1993. 81:660–664.

19. Cohen I, Rosen DJ, Shapira J, Cordoba M, Gilboa S, Altaras MM, et al. Endometrial changes with tamoxifen: Comparison between tamoxifen-treated and nontreated asymptomatic post-menopausal breast cancer patients. Gynecol Oncol. 1994. 52:185–190.

20. Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet. 1994. 343:1318–1321.

21. Fisher B, Constantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for the prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998. 90:1371–1388.

22. Fisher B, Constantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994. 86:527–537.

23. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst. 1995. 87:645–651.

24. Curtis RE, Boice JD, Shriner DA, Hankey BF, Fraumeni JF. Second cancers after adjuvant therapy for breast cancer [brief communication]. J Natl Cancer Inst. 1996. 88:332–334.

25. Ismail SM. Pathology of endometrium treated with tamoxifen. J Clin Pathol. 1994. 47:827–833.

26. Cheng WF, Lin HH, Thorng PL, Huang SC. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol. 1997. 66:233–237.

27. Chang J, Powles TJ, Ashley SE, Iveson T, Gregory RK, Dowsett M. Variation in endometrial thickening in women with amenorrhea on tamoxifen. Breast Cancer Res Treat. 1998. 48:81–85.

28. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfversward C, et al. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet. 1989. 1:117–120.

29. Magriples U, Naftolin F, Schwartz PE, Carcangiu ML. High-grade endometrial carcinoma in tamoxifen treated breast cancer patients. J Clin Oncol. 1993. 11:485–490.

30. Seoud MA, Johnson J, Weed JC Jr. Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet Gynecol. 1993. 82:165–169.

31. Stearns V, Gelmann EP. Does tamoxifen cause cancer in humans? J Clin Oncol. 1998. 16:779–792.

32. Gerber B, Krause A, Muller H, Reimer T, Kulz T, Makovitzky J, et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: A prospective long-term study using transvaginal ultrasound. J Clin Oncol. 2000. 18:3464–3470.

33. ATAC Trialists Group. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005. 365:60–62.

34. Duffy S, Jackson TL, Lansdown M, Philips K, Wells M, Pollard S, et al. The ATAC (arimidex, tamoxifen, alone or in combination) adjuvant breast cancer trial: Baseline endometrial sub-protocol data on the effectiveness of transvaginal ultrasonography and diagnostic hysteroscopy. Hum Reprod. 2005. 20:294–301.

35. Duffy S, Jackson TL, Lansdown M, Philips K, Wells M, Pollard S, et al. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod. 2005. 21:545–553.

36. Jolles CJ, Smotkin D, Ford KL, Jones KP. Cystic ovarian necrosis complicating tamoxifen therapy for the breast cancer in a premenopausal woman: Case report. J Reprod Med. 1990. 35:299–300.

37. Mourits MJ, de Vries EG, Willemse PH, ten Hoor KA, Hollema H, Sluiter WJ, et al. Ovarian cysts in women receiving tamoxifen for breast cancer. Br J Cancer. 1999. 79:1761–1764.

38. Radvin PM, Fritz NF, Tormey DC, Jordan VC. Endocrine status of premenopausal node positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Res. 1988. 48:1026–1029.

39. Powles TJ, Jones AL, Ashley SE, O'rien MER, Tidy VA, Treleaven J, et al. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat. 1994. 31:73–82.

40. Christensen JT, Boldsen JL, Westergaard JG. Functional ovarian cysts in premenopausal and gynecologically healthy women. Contraception. 2002. 66:153–157.